Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$10.73 USD
-0.28 (-2.54%)
Updated May 10, 2024 04:00 PM ET
After-Market: $10.72 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 101 - 120 ( 121 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Data From First Phase III HEPLISAV Study Expected Within 8 Weeks
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Q1:2011 Financial Recap; Expect Phase III HEPLISAV Data in Mid-2011
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Assuming Coverage with OUTPERFORM and Lowering Fair Value to $6 from $9; Optimistic on HEPLISAV
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Pipeline Progress: Universal Flu Vaccine and Hepatitis B Therapeutic Vaccine
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Heplisav Passes 4th DSMB Safety Review; Raising PT to $9
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences -MAC Best Ideas Conference - Key Takeaways New York City.
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Q2 Earnings Non-Event; Awareness on the Rise as Phase III Data Release Draws Near.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Heplisav Studies on Track; Nature Publication Highlights Upside; Reiterate OP.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Betting on Heplisav: Assuming Coverage, Upgrading to Relative OUTPERFORM and Increasing Price Target to $6
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Summary of Poster Presentations and Update of DAA Cross Comparison Table
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K